硝苯地平缓释片联合厄贝沙坦治疗高血压的临床疗效与安全性

Clinical Efficacy and Safety of Nifedipine Sustained Release Tablets Combined with Irbesartan in the Treatment of Hypertension

目的探讨硝苯地平缓释片联合厄贝沙坦治疗高血压的临床疗效与安全性。方法方便选择2017年1月—2018年1月期间该院收治的原发性高血压患者200例为研究对象,均分为两组,对照组100例患者采用硝苯地平缓释片,观察组100例患者采用厄贝沙坦片联合硝苯地平缓释片,比较两组患者舒张压及收缩压水平。结果观察组患者治疗后的收缩压(121.5±7.4)mmHg,舒张压(73.5±6.1)mmHg,控制效果优于对照组收缩压(133.5±8.6)mmHg,舒张压(84.4±7.2)mmHg,比较差异有统计学意义(t=3.025、2.890,P<0.05);观察组患者治疗总有效率93.0%明显高于对照组患者74.0%,组间差异有统计学意义(χ^2=4.166,P<0.05);两组的不良反应发生率为3.0%和15.0%,观察组的不良反应发生率低于对照组,差异有统计学意义(χ^2=5.423,P<0.05)。结论厄贝沙坦片联合硝苯地平缓释片治疗原发性高血压患者的应用效果非常显著,降低了不良反应发生率,提高了治疗效果,值得应用。

Objective To investigate the clinical efficacy and safety of nifedipine sustained release tablets combined with irbesartan in the treatment of hypertension. Methods A total of 200 patients with essential hypertension admitted to our hospital from January 2017 to January 2018 were convenient enrolled in the study. They were divided into two groups. The control group received 100 patients with nifedipine sustained-release tablets. One hundred patients in the observation group were treated with irbesartan tablets combined with nifedipine sustained-release tablets to compare diastolic blood pressure and systolic blood pressure levels. Results The systolic blood pressure (121.5±7.4)mmHg and diastolic blood pressure (73.5±6.1)mmHg were observed in the observation group. The control effect was better than the control group (133.5±8.6)mmHg and diastolic blood pressure (84.4±7.2)mmHg, with significance (t=3.025, 2.890, P<0.05);the total effective rate of treatment in the observation group was 93.0% significantly higher than that in the control group (74.0%), the difference between the groups was statistically significant (χ^2=4.166, P<0.05);The incidence of adverse reactions in the group was 3.0% and 15.0%. The incidence of adverse reactions in the observation group was lower than that in the control group, which was statistically significant (χ^2=5.423, P<0.05). Conclusion The application effect of irbesartan tablets combined with nifedipine sustained-release tablets in the treatment of patients with essential hypertension is very significant, reducing the incidence of adverse reactions and improving the therapeutic effect, which is worthy of application.